ArticleFrontiers in oncology2025
Multidisciplinary management of surgery and postoperative recurrence in stage IV gallbladder cancer following conversion therapy: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidisciplinary treatment with conversion surgery after radiological complete response of liver metastasis to gemcitabine, cisplatin, and durvalumab in metastatic distal cholangiocarcinoma.Clinical journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 61-year-old female patient presented with a 10-day history of right upper abdominal pain and was subsequently diagnosed with stage IV gallbladder cancer based on preoperative imaging and pathological evaluation. Following multidisciplinary discussion, a triple-agent combination therapy was initiated. Although the patient developed severe grade II cutaneous toxicity during treatment, a significant clinical response was achieved, and symptoms were effectively relieved with supportive management. After four months of conversion therapy, the patient underwent successful radical surgical resection. Five months postoperatively, isolated hepatic metastases were identified, and a multidisciplinary team subsequently recommended radiofrequency ablation. The patient is currently receiving maintenance therapy with immune checkpoint inhibitors. At the most recent follow-up, the patient remains disease-free, with an overall survival of 18 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.